Literature DB >> 20384583

Molecular pathways in the progression of hormone-independent and metastatic prostate cancer.

B Wegiel1, S Evans, R Hellsten, L E Otterbein, A Bjartell, J L Persson.   

Abstract

Once prostate cancer becomes castration resistant, cancer cells may rapidly gain the ability to invade and to metastasize to lymph nodes and distant organs. The progression through hormone-dependent to hormone-independent/castration-resistant and metastatic PCa is poorly understood. In this review paper, we provide an overview on the cellular and molecular mechanisms underlying the process of tumor cell invasion and metastasis in prostate cancer. We specifically present the most recent findings on the role of multiple cellular signaling pathways including androgen receptor (AR), mitogen-activated protein kinases (MAPK), Akt, transforming growth factor b (TGFb interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) in the development of hormone-independent/castration-resistant prostate cancer. In addition, we also discuss the recent findings on signatures of gene expression during prostate cancer progression. Our overviews on the novel findings will help to gain better understanding of the complexity of molecular mechanisms that may play an essential role in the development of castration-resistant and metastatic prostate cancer. It will also shed light on the identification of specific targets and the design of effective therapeutic drug candidates.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20384583     DOI: 10.2174/156800910791208562

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  14 in total

1.  Serum prosaposin levels are increased in patients with advanced prostate cancer.

Authors:  Shahriar Koochekpour; Siyi Hu; Cruz Vellasco-Gonzalez; Ruiz Bernardo; Gissu Azabdaftari; Guodong Zhu; Haiyen E Zhau; Leland W K Chung; Robert L Vessella
Journal:  Prostate       Date:  2011-05-31       Impact factor: 4.104

Review 2.  The changing therapeutic landscape of castration-resistant prostate cancer.

Authors:  Timothy A Yap; Andrea Zivi; Aurelius Omlin; Johann S de Bono
Journal:  Nat Rev Clin Oncol       Date:  2011-08-09       Impact factor: 66.675

3.  Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression.

Authors:  Punit Saraon; Daniela Cretu; Natasha Musrap; George S Karagiannis; Ihor Batruch; Andrei P Drabovich; Theodorus van der Kwast; Atsushi Mizokami; Colm Morrissey; Keith Jarvi; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2013-02-26       Impact factor: 5.911

4.  Enhanced shedding of extracellular vesicles from amoeboid prostate cancer cells: potential effects on the tumor microenvironment.

Authors:  Jayoung Kim; Samantha Morley; Minh Le; Denis Bedoret; Dale T Umetsu; Dolores Di Vizio; Michael R Freeman
Journal:  Cancer Biol Ther       Date:  2014-01-14       Impact factor: 4.742

5.  Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer.

Authors:  Saswati Mahapatra; R Jeffrey Karnes; Michael W Holmes; Charles Y F Young; John C Cheville; Manish Kohli; Eric W Klee; Donald J Tindall; Krishna Vanaja Donkena
Journal:  AAPS J       Date:  2011-05-11       Impact factor: 4.009

6.  Selective cell cycle arrest and induction of apoptosis in human prostate cancer cells by a polyphenol-rich extract of Solanum nigrum.

Authors:  Akbar Nawab; Vijay S Thakur; Mohammad Yunus; Abbas Ali Mahdi; Sanjay Gupta
Journal:  Int J Mol Med       Date:  2011-11-10       Impact factor: 4.101

7.  CK2-NCoR signaling cascade promotes prostate tumorigenesis.

Authors:  Jung-Yoon Yoo; Beom Jin Lim; Hyo-Kyoung Choi; Soon Won Hong; Ho Sung Jang; Changsoo Kim; Kyung-Hee Chun; Kyung-Chul Choi; Ho-Geun Yoon
Journal:  Oncotarget       Date:  2013-07

8.  Enhanced inhibition of prostate tumor growth by dual targeting the androgen receptor and the regulatory subunit type iα of protein kinase a in vivo.

Authors:  Iris E Eder; Martina Egger; Hannes Neuwirt; Christof Seifarth; Danilo Maddalo; Andreas Desiniotis; Georg Schäfer; Martin Puhr; Jasmin Bektic; Andrew C B Cato; Helmut Klocker
Journal:  Int J Mol Sci       Date:  2013-06-04       Impact factor: 5.923

9.  The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells.

Authors:  D J P Henderson; A Byrne; K Dulla; G Jenster; R Hoffmann; G S Baillie; M D Houslay
Journal:  Br J Cancer       Date:  2014-02-11       Impact factor: 7.640

10.  DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells.

Authors:  Samia B Bachmann; Sandra C Frommel; Rosalba Camicia; Hans C Winkler; Raffaella Santoro; Paul O Hassa
Journal:  Mol Cancer       Date:  2014-05-27       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.